TIAP portfolio company Forbius announced on August 24, 2020 that they have entered into an acquisition deal with Bristol Myers Squibb. BMS is adding lead TGF-beta asset to its portfolio.
TIAP was one of the earliest investors and partners with Forbius in 2011/12. This is a big win for Forbius CEO Dr. Tikhomirov and the Canadian research and innovation community. Forbius (formerly Formation Biologics) is a clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic ...
Toronto, Ontario, June 04, 2020 (GLOBE NEWSWIRE) -- Toronto Innovation Acceleration Partners (TIAP) announced today the launch of a new LAB150 project aimed at developing a novel therapeutic agent for immuno-oncology. The research for the promising new approach comes from Dr. Jean Gariépy and his lab at Sunnybrook Research Institute, a TIAP Member institution.
The last several years has seen the introduction of a new blockbuster class of drugs for treating cancers – specifically, the immune checkpoint inhibitors (ICIs). These drugs act ...
– Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials –
– Series A Financing led by the Perceptive Xontogeny Venture Fund –
TORONTO, March 31, 2020 (GLOBE NEWSWIRE) -- Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has closed a US$21 million Series A Financing led by the Perceptive Xontogeny Venture Fund (“PXV Fund”).
The proceeds from the financing will fund Phase 1 and ...
Toronto, ON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Notch Therapeutics, a company in the emerging field of gene-modified T cell therapy, has been created to commercialize a revolutionary technology that creates allogeneic (donor) gene-edited T cells from stem cells on an industrial scale, efficiently making T cell therapies that are clinically robust and of a consistently high quality. Notch is actively pursuing industry partnerships.
The founders of Notch - Sunnybrook Health Sciences Centre, University of Toronto (UoT), Toronto Innovation Acceleration Partners (TIAP) ...
Our portfolio company, Encycle Therapeutics, has been acquired by Danish Zealand Pharma. The transaction strengthens the leadership of Zealand Pharma (NASDAQ: ZEAL) in peptide therapeutics and in targeting gastrointestinal diseases with the addition of a pre-clinical, orally-delivered macrocycle peptide (integrin alpha-4-beta-7 inhibitor). Encycle is founded on research coming from University of Toronto - a TIAP member institution. Read more here: http://bit.ly/2W2hH4N
TORONTO, Oct. 3, 2019 /PRNewswire/ -- AmacaThera Inc. (www.amacathera.ca) is pleased to announce the closing of its US $3.6M seed financing round. A first close of the round was led by Sprout BioVentures/ Viva Biotech with participation from Grey Sky Venture Partners, and the round was recently completed with an investment by Toronto-based Lumira Ventures.
Commenting on the closing of the round, Dr. Molly Shoichet, Ph.D., Co-Founder and Chief Scientific Officer of AmacaThera stated: "We are thrilled to have the Lumira team as part ...
Toronto, ON, Feb. 27, 2019 (GLOBE NEWSWIRE) -- MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by prominent teams at The Hospital for Sick Children (SickKids) and the University of Toronto, both of which are Members of MaRS Innovation. LAB150 is a partnership between MaRS Innovation and Evotec AG with the goal of accelerating academic research towards commercial outcomes by providing funding and access to pharmaceutically validated platforms ...
Toronto, ON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Fibrocor Therapeutics, a privately held Canadian company, and Galapagos NV, a Belgo-Dutch pharmaceutical research company, have announced the formation of a partnership for the development of therapeutics to treat fibrotic diseases of the kidney and other organs.
In 2017 MaRS Innovation founded, and subsequently seed-funded, Fibrocor. The company is based on research from two of MaRS Innovation’s Member institutions, St. Michael’s Hospital and Sinai Health Systems – specifically, from the labs of Drs. Richard ...
KIRKLAND, Quebec and TORONTO, April 09, 2018 (GLOBE NEWSWIRE) -- Pfizer Canada is proud to announce an $800,000 contribution to MaRS Innovation to support the vision and mission of MaRS Innovation by providing funding for new ideas or technologies in the health sciences including; therapeutics, diagnostic and treatment tools, manufacturing technologies, and technologies that enable health sciences research.
The MaRS Innovation – Pfizer Translational Research Fund will be managed by MaRS Innovation and projects in the area of cardiovascular disease, inflammation, immunology, ...
VANCOUVER and TORONTO, Canada — January 8, 2018 - Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, has received support of up to $350,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). In addition, The Centre for Drug Research and Development (CDRD) and MaRS Innovation have contributed follow on funding to the Company’s existing convertible note.
Zucara recently defined its lead drug candidate, ZT-01, and ...